Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1009 clinical trials
featured
TRANSFORM – B cell non-Hodgkin lymphoma - JCAR017-BCM-003 - US  

) aggressive Non-Hodgkin lymphoma (NHL) to compare safety and efficacy between the standard of care (SOC) strategy versus JCAR017 (also known as lisocabtagene maraleucel or liso-cel). Subjects will be randomized

  • 2946 views
  • 05 Jan, 2021
  • 10 locations
featured
Phase 1/2 Study Of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin’s Lymphoma

Phase 1/2 Study Of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin’s Lymphoma

  • 590 views
  • 23 Nov, 2020
  • 5 locations
featured
TRANSCEND - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - TRANSCEND-CLL-004 - US  

Phase 2 single-arm, multi-cohort study to determine the efficacy and safety of JCAR017 (autologous T cells expressing anti-CD19 chimeric antigen receptor) in adult subjects with aggressive B-NHL (diffuse large B-cell lymphoma (DLBCL) NOS [de novo or transformed follicular lymphoma (tFL)], double/triple-hit lymphoma [DHL/THL], follicular lymphoma Grade 3B [FL3B], primary central …

  • 1875 views
  • 15 Jan, 2021
  • 15 locations
featured
  • 36 views
  • 11 Jun, 2020
  • 1 location
featured
Phase 1/2 Study Of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Patients With Follicular Non-Hodgkin’s Lymphoma

This is a multi-center Phase 1/2 open label trial of intratumoral G100 in patients with low grade NHL. Patients with NHL will be enrolled and receive G100 to an accessable tumor mass. Clinical response will be evaluated in the injected lesion and systemic (abscopal) responses will be evaluated in distal …

lymphoma
non-hodgkin's lymphoma
lymphomas
  • 73 views
  • 22 Dec, 2020
  • 31 locations
featured
HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma

of agents such as VEGF, mTOR inhibitors and immunotherapy (high-dose (HD) IL-2 or immune-checkpoint inhibitors). Long-term survival can be achieved with high-doses IL-2 or immune-checkpoint inhibitors

renal cell cancer
primary cancer
metastatic cancer
clear cell carcinoma
carcinoma
  • 144 views
  • 22 Dec, 2020
  • 1 location
featured
Diffuse Large B Cell/Non-Hodgkin Lymphoma

Diffuse Large B Cell/Non-Hodgkin Lymphoma

  • 902 views
  • 08 Nov, 2020
  • 1 location
featured
PILOT - B cell non-Hodgkin lymphoma - TRANSCEND-PILOT-017006 - US  

single line of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) and are ineligible for hematopoietic stem cell transplant (based on age, performance status, and/or comorbidities

  • 2758 views
  • 15 Dec, 2020
  • 12 locations
featured
Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (C/SLL) or Non-Hodgkin Lymphoma (NHL)

People with previously treated Lymphomas are asked to participate in a research study being conducted by Northwell Health.  

  • 17 views
  • 23 Jul, 2020
  • 1 location
featured
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

  • 8 views
  • 08 Nov, 2020
  • 1 location